Press Releases

100% procedural success rate in a 30 patient study using the new CGuardTM Embolic Prevention System with no procedural related complications and zero strokes at 6-month follow up Companion Editorial Highlights Need for More Effective Management of Carotid Artery Stenosis for Stroke Prevention   BOSTON, MA – October 17, 2016 – InspireMD, Inc. (NYSE MKT:… Read More

BOSTON, Mass. – October 13, 2016 – InspireMD, Inc. (NYSE MKT: NSPR, NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced that President and Chief Executive Officer James Barry, PhD will present at the Dawson James Securities 2nd Annual Growth Stock Conference on Thursday,… Read More

BOSTON, MA – October 6, 2016 – InspireMD, Inc. (NYSE MKT: NSPR, NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced that in conjunction with the 1-for-25 reverse stock split announced last week following the Company’s special meeting of stockholders, the number of shares… Read More

BOSTON, MA – September 28, 2016 – InspireMD, Inc. (NYSE MKT: NSPR, NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced a 1-for-25 reverse split of its common stock, effective as of October 7, 2016.  Beginning on October 10, 2016, the Company’s common stock… Read More

BOSTON, MA – September 7, 2016 – InspireMD, Inc. (NYSE MKT: NSPR, NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced the appointment of Thomas Kester to the Company’s Board of Directors and Chairman of the Company’s Audit Committee. Mr. Kester brings over 40… Read More

 Company to Host Conference Call Today at 4:30pm ET BOSTON, MA – August 9, 2016 – InspireMD, Inc. (NYSE MKT: NSPR, NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced financial and operating results for the second quarter ended June 30, 2016, and provided… Read More

BOSTON, MA – August 2, 2016 – InspireMD, Inc. (NYSE MKT: NSPR, NSPR.WS), a leader in embolic protection systems, announced today that it will release its financial results for the second quarter ended June 30, 2016 on Tuesday, August 9 after the market close, followed by a conference call at 4:30 p.m. ET to review… Read More

BOSTON, MA – August 1, 2016 — InspireMD, Inc. (NYSE MKT: NSPR, NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic protection systems (EPS), neurovascular devices and thrombus management technologies, today announced the listing of the Company’s 44,242,424 previously issued warrants on the NYSE MKT (the “Exchange”).  Beginning at the market open on August 1,… Read More

BOSTON, MA – July 21, 2016 — InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection systems (EPS), neurovascular devices and thrombus management technologies, today announced that the NYSE MKT (the “Exchange”) has notified the Company that it has regained compliance with the NYSE MKT continued listing standards. InspireMD received… Read More

BOSTON, MA – July 7, 2016 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced the closing of a “best efforts” public offering of 442,424 shares of Series B Convertible Preferred Stock and accompanying warrants to purchase up to… Read More